Navigation Links
Compound Reverses Huntington's Symptoms in Mice
Date:9/16/2008

Treatment slowed reduction of brain size, improved motor functioning, study finds

TUESDAY, Sept. 16 (HealthDay News) -- An experimental compound called HDACi 4b reversed Huntington's disease symptoms in mice genetically altered to develop the disease, say researchers at the Scripps Research Institute in California.

Huntington's is an inherited neurological disease that affects people's movement and thinking ability. There is no cure or treatment that can reverse or slow progression of the physical and mental deficits caused by the disease.

"We found that (HDACi 4b) can target the expression of several hundred genes in the brain and reverse the abnormalities caused by a single mutant protein. This suggests that a treatment for Huntington's disease that targets a core pathogenic mechanism might be close at hand -- closer than previously imagined," study author Elizabeth A. Thomas, an assistant professor in department of molecular biology, said in a Scripps news release.

In this study, the mice were given the compound after they first started to develop symptoms of Huntington's. The treatment slowed the loss of body weight and reduction of brain size, and improved their appearance and motor functioning.

"The benefit seen was surprising, and immensely exciting, because it suggests this compound could form the basis of truly relevant therapeutic treatment for Huntington's disease," Thomas said. "The mice that were destined to develop Huntington's disease receiving the treatment did significantly better than the mice who didn't receive the drug."

The findings were published this week in the early edition of the Proceedings of the National Academy of Sciences. The study received funding from Massachusetts-based Repligen Corp., which holds several patent applications related to HDAC (histone deacetylase) inhibitors, a class of agents that include HDACi 4b.

Other HDAC inhibitors produced some beneficial results in test animals but were deemed too toxic.

"[HDACi 4b] proved to be therapeutically superior, as well as less toxic than other HDAC inhibitors that had been tested for Huntington's disease," Thomas said.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about Huntington's disease.



-- Robert Preidt



SOURCE: Scripps Research Institute, news release, Sept. 15, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Coloring Compound in Fruits, Veggies May Cut Colon Cancer Risk
2. Sugary Sodas High in Diabetes-Linked Compound
3. Red wine compound shown to prevent prostate cancer
4. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
5. A Chinese medicine compound has satisfactory anti-cancer effects on hepatocellular carcinoma
6. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
7. Organon Signs an Exclusive, Worldwide Licence Agreement on Advanced Antithrombotic Compounds With Endotis Pharma
8. Primus Innovations and Health Robotics Launch Strategic Partnership to Accelerate Transformation in Chemotherapy Compounding
9. Cannabis Compound May Stop Metastatic Breast Cancer
10. Prostate Cancer Treatments Often Compound Existing Health Problems
11. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 09, 2016 , ... An inventor from Cana, Va., wanted to fulfill the ... amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates ... be set up in a matter of minutes, or even seconds. The SAFETY STRAP ...
(Date:12/9/2016)... PA (PRWEB) , ... December 09, 2016 , ... "I ... said an inventor from Winchester, Va. "I thought that if the nebulizer had a ... treatments rather than fearing them." , He developed the patent-pending NEBY to avoid the ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking ... registration today for its 33rd Annual Issues & Research Conference, March 2-3, ... theme of the conference is “Persistent Challenges and New Opportunities: Using Research to ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) ... , the ultimate weight loss and wellness program, at their world headquarters of Omni ... provide immediate and long-term results to anyone seeking weight loss, personal development, a healthy ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... FRISCO, Texas , Dec. 8, 2016 /PRNewswire/ ... new program that brings leading-edge laboratory services and ... the United States , allowing more doctors ... and health care management solutions. Logo ... Hospital systems, under pressure to ...
(Date:12/8/2016)... , December 8, 2016 Information products ... metrics in Scopus , the world,s largest abstract ... access to comprehensive metrics for journals from over 5,000 publishers. The ... which journals to subscribe to and when to adjust a journal,s ... , , ...
Breaking Medicine Technology: